A 12-week, Randomized, Double-blind, Placebo-controlled Exploratory Study to Assess the Antiepileptic Activity of BGG492 Given Orally as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures.

Trial Profile

A 12-week, Randomized, Double-blind, Placebo-controlled Exploratory Study to Assess the Antiepileptic Activity of BGG492 Given Orally as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Selurampanel (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Dec 2012 Planned number of patients changed from 57 to 115 as reported by European Clinical Trials Database.
    • 12 Nov 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Aug 2010 Actual initiation date (Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top